EUVIMEDEUVIMED entdecken
Crossref

Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV‐1‐infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS‐MIE‐BIRIDER study)

Florian Lemaitre iD, Jennifer Lagoutte-Renosi, Marie-Claude Gagnieu, François Parant, Nicolas Venisse, Matthieu Grégoire iD, Stéphane Bouchet, Rodolphe Garraffo, Minh P Lê iD, Patrice Muret, Emmanuelle Comets, Caroline Solas iD und 2 weitere

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.15890 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Florian Lemaitre und 13 weiteren Autor:innen. Beteiligte Einrichtung: Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail)-UMR_S 1085, Rennes, France. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Anti-HIV Agents, Acquired Immunodeficiency Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended as a switch option in virologically suppressed HIV patients. Literature suggests that virological failure with dual therapy could possibly relate to subtherapeutic drug concentrations. In this study, we aimed at describing the DTG and RPV trough plasma concentrations (Cmin) and plasma HIV‐1 RNA viral load (VL) during maintenance dual therapy.

Methods

We performed a retrospective analysis of DTG and RPV therapeutic drug monitoring in people living with HIV/AIDS (PLWHA) with dual therapy in 9 French centres. DTG and RPV trough plasma concentrations were estimated using a Bayesian approach to predict Cmin. The relationship between the pharmacokinetics of DTG and RPV and VL > 50 copies (cp)/mL was explored using joint nonlinear mixed models. The frequency of subtherapeutic threshold (DTG Cmin below 640 ng/mL and RPV Cmin below 50 ng/mL) were compared between PLWHA presenting VL > 50 cp/mL or not during the study.

Results

At baseline, 209 PLWHA were enrolled in the study. At week 48, 19 people living with HIV/AIDS (9.1%) discontinued their treatment and 15 PLWHA (7.1%) exhibited VL > 50 cp/mL. Six PLWHA out of 15 (40.0%) with VL > 50 cp/mL during the follow‐up had at least 1 Cmin below the respective thresholds while only 26/194 patients (13.4%) without virological replication had at least 1 concentration below the threshold ( P = .015).

Conclusion

A majority of PLWHA receiving DTG/RPV maintenance dual therapy demonstrated VL < 50 cp/mL but virological replication was more frequent in people living with HIV/AIDS with subtherapeutic Cmin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1Anti-HIV AgentsAcquired Immunodeficiency SyndromeHumansRetrospective StudiesBayes TheoremDrug MonitoringRilpivirineOxazinesPyridonesHeterocyclic Compounds, 3-RingViral LoadDolutegravir

Stichwörter der Autor:innen

antiretroviralsintegrase strand transfer inhibitorsnon-nucleoside reverse transcriptase inhibitorspharmacodynamicspharmacokinetics

Substanzen

Anti-HIV AgentsRilpivirineOxazinesPyridonesHeterocyclic Compounds, 3-RingDolutegravir

Autor:innen und Institutionen

  • Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail)-UMR_S 1085, Rennes, France.
  • MPFRPV, Université de Franche-Comté, Besançon, France.
  • Service de Pharmacologie Clinique et Toxicologie, CHU Besançon, Besançon, France.
  • Hospices Civils de Lyon - Groupement Hospitalier Sud - Service de Biochimie et Biologie Moléculaire - UM Pharmacologie-Toxicologie, Pierre-Benite, France.
  • Laboratoire de Toxicologie et Pharmacocinétique, CHU Poitiers, Poitiers, France.
  • CIC Inserm 1402, Poitiers, France.

ORCID-Profile: Florian Lemaitre, Matthieu Grégoire, Minh P Lê, Caroline Solas

Zitieren

APA

Lemaitre, F., Lagoutte-Renosi, J., Gagnieu, M. C., Parant, F., Venisse, N., Grégoire, M., Bouchet, S., Garraffo, R., Lê, M. P., Muret, P., Comets, E., Solas, C., Peytavin, G., & ANRS-MIE-BIRIDER Study group on behalf of the Clinical Pharmacology Group of ANRS-MIE AC43 (2024). Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV‐1‐infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS‐MIE‐BIRIDER study). British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15890

Vancouver

Lemaitre F, Lagoutte-Renosi J, Gagnieu MC, Parant F, Venisse N, Grégoire M, et al. Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV‐1‐infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS‐MIE‐BIRIDER study). British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.15890

BibTeX
@article{Lemaitre2024,
  author = {Lemaitre, Florian and Lagoutte-Renosi, Jennifer and Gagnieu, Marie-Claude and Parant, François and Venisse, Nicolas and Grégoire, Matthieu and Bouchet, Stéphane and Garraffo, Rodolphe and Lê, Minh P and Muret, Patrice and Comets, Emmanuelle and Solas, Caroline and Peytavin, Gilles and ANRS-MIE-BIRIDER Study group on behalf of the Clinical Pharmacology Group of ANRS-MIE AC43, ANRS-MIE-BIRIDER Study group on behalf of the Clinical Pharmacology Group of ANRS-MIE AC43},
  title = {Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV‐1‐infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS‐MIE‐BIRIDER study)},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.15890}
}
Kostenlos starten →